Sulfalene
Appearance
(Redirected from Dalysep)
Clinical data | |
---|---|
Trade names | Eadazine, Kelfizina, Kelfizine W, Longum |
Other names | Sulfametopyrazine |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral[1] |
ATC code | |
Pharmacokinetic data | |
Protein binding | 60 to 80%[1] |
Elimination half-life | 60 to 65 hours[1] |
Excretion | Urinary[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.278 |
Chemical and physical data | |
Formula | C11H12N4O3S |
Molar mass | 280.30 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Sulfalene (INN, USAN) or sulfametopyrazine (BAN) is a long-acting sulfonamide antibacterial used for the treatment of chronic bronchitis, urinary tract infections and malaria.[2][3] As of 2014 there were only two countries in which it is currently still marketed: Thailand and Ireland.[3]
It was discovered by researchers at Farmitalia and first published in 1960 and was marketed as Kelfizina.[4][5]
See also
[edit]References
[edit]- ^ a b c d "Sulfalene". MIMS Drug Information System. Retrieved 26 August 2011.
- ^ DrugBank DB00664
- ^ a b Brayfield A, ed. (9 May 2013). "Sulfametopyrazine". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 28 March 2014.
- ^ Baruffa G (1966). "Clinical trials in Plasmodium falciparum malaria with a long-acting sulphonamide". Transactions of the Royal Society of Tropical Medicine and Hygiene. 60 (2): 222–4. doi:10.1016/0035-9203(66)90030-7. PMID 5332105.
- ^ Per prior citation, the first publication: Camerino B, Palamidessi G (1960). "Derivati della parazina II. Sulfonamdopir". Gazz Chim Ital (in Italian). 90: 1802–1815.